Pharming announces publication of data from Phase 3 Study of l...
- Written by LATEST ASIANET NEWS RELEASES
- Category: Asia Net
LEIDEN, Netherlands, Dec. 7, 2022 /PRNewswire-AsiaNet/-- Leniolisib was well tolerated and significant improvement over placebo was notable in the co-primary endpoints, reflecting a favorable impact on patients' immune dysregulation and deficiencyThe peer-reviewed publication heightens international......




